… COVID-19 outbreak are urgently needed. To facilitate the better and faster development
of therapeutic COVID-19 … drugs, including repurposing existing antiviral agents, network-based …

… Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as … in
COVID-19 patients of these antiviral agents and provided the potential antiviral agent options …

… 6-fluoro-3-hydroxy-2pyrazinecarboxamide) is an antiviral agent that selectively and potently
inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses. Favipiravir undergoes …

… Antiviral therapies have greatly improved the clinical outcome in COVID-19 patients, especially
… Here, we discuss the successes and challenges of COVID-19 antiviral therapies and …

… As the scale of the ongoing COVID-19 outbreak has reached … COVID-19 remain to be
defined, significant interest exists in repurposing existing antiviral agents for use against COVID-19…

… Most of the antiviral discovery efforts are focused on the repurposing of approved or clinical
… antiviral agents that are currently under investigation in clinical trials for COVID-19. These …

… Recently, it was also reported that, NIC exhibited in vitro antiviral activity … for COVID-19. The
plausible therapeutic mechanisms by which NIC acts as an antiviral agent against COVID-19 …

… antiviral agent originally designed for the treatment of Alphavirus infections, into a potential
drug for the prevention and treatment of COVID-19. … As COVID-19 spread, the timeline for the …

… safe antiviral agent in older patients with COVID-19 aged ≥80 years, 29 this study did not
assess the safety of novel oral antiviral agents in the treatment of older people with COVID-19. …

… for the COVID-19 disease. This Review addresses the application of these broad-spectrum
CBNs as antimicrobial agents by analyzing a large number of antiviral … to treat COVID-19. …